GERN:NSD-Geron Corporation (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 4.57

Change

0.00 (0.00)%

Market Cap

USD 2.75B

Volume

9.25M

Analyst Target

USD 4.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing GERN

CNCR Loncar Cancer Immunothera.. 3.66 % 0.79 %

N/A

USD 0.01B
WDNA:LSE WisdomTree BioRevolution .. 2.73 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.70 % 0.00 %

N/A

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 2.69 % 0.00 %

N/A

USD 3.87M
WDNA 2.57 % 0.00 %

N/A

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 116.59% 66% D+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 116.59% 66% D+ 82% B
Trailing 12 Months  
Capital Gain 115.57% 62% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.57% 62% D 81% B-
Trailing 5 Years  
Capital Gain 243.61% 69% C- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 243.61% 69% C- 85% B
Average Annual (5 Year Horizon)  
Capital Gain 29.84% N/A N/A 84% B
Dividend Return 29.84% N/A N/A 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.65% N/A N/A 31% F
Risk Adjusted Return 52.68% N/A N/A 80% B-
Market Capitalization 2.75B 91% A- 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector